NovaBiotics contribution to ECCMID 2017

Date posted: 13-Apr-2017

Category: Events

NovaBiotics, the clinical-stage anti-infectives biotechnology company, will be presenting five posters/e-posters and speaking at the at the 27th European Congress of Clinical Microbiology and Infectious Diseases’ (ECCMID) Pipeline Corner symposium. The team, led by CEO Dr Deborah O’Neil and accompanied by Daniel Smith, Dr Douglas Fraser-Pitt, Dr Laura Katvars and Dr Derry Mercer, will be presenting an update to NovaBiotics’ Cysteamine and novel modified antimicrobial peptide (AMP) platforms. Pipeline Corner is a symposium for invited innovative companies to provide an overview of their R&D pipelines and present recent advances in early-stage programmes.

Dr Deborah O’Neil said “NovaBiotics is on the front line of discovery and development of novel solutions for the global antimicrobial resistance pandemic. We have developed two unique platforms which leverage the immune system’s innate defence mechanisms. Product candidates from both platforms are already in advanced stages of clinical development. Our unique technological approach has significant potential and I look forward to sharing developments with colleagues and peers at ECCMID 2017”.

The presentation, which will take place on Sunday 23 April at 12:30PM in Foyer E, will provide an overview of the platforms and review potential demonstrated in development thus far. A link to the presentation can be found here. NovaBiotics Presentation April 2017

The other members of the NovaBiotics team will present more detail on both the Cysteamine and antimicrobial platforms and also the company’s clinical stage anti-infective candidates in their posters and brief e-poster presentations throughout the rest of the conference, programme for which can be found here http://www.eccmid.org/ and the full presentation schedule is as follows:

Symposium	Presenter(s)	Presentation	Date	Time	Location
Pharmacoepidemiology, Improved Prescribing and Antibiotic Stewardship	Mr Daniel Smith	Cysteamine has a broad spectrum antimicrobial utility against a wide variety of emerging pathogens of cystic fibrosis associated lung disease	Saturday 22 April - Tuesday 25 April	08:45-15:30	ePoster Viewing Area
New Antibiotics - New Approaches	Dr Douglas Fraser-Pitt	Cysteamine As An Antibiotic Resistance Breaker	Sunday 23 April	13:30-14:30	ePoster Area 3
Drugs against Gram-Positives-More Data	Dr Laura Katvars	Novarifyn, a novel antimicrobial peptide rapidly active against multi-drug-resistant Staphylococcus aureus and Acinetobacter baumannii	Monday 24 April	12:30-13:30	Paper Poster Area
Antifungal Drugs and Treatment I	Dr Laura Katvars & Dr Derry Mercer	NP339 as a novel approach against respiratory fungal infections & Antifungal activity of NP339 in vivo in respiratory models of fungal infection	Tuesday 25 April	12:30-13:30	Paper Poster Area

About NovaBiotics

NovaBiotics is a leading clinical-stage biotechnology company focussed on developing first-in-class antibacterial and antifungal solutions to combat the global Antimicrobial Resistance pandemic. The Company’s has both a classic and novel approach to combatting AMR, both of which leverage the innate immune system’s defence mechanisms. The Company’s robust technology has been validated through successful development, from concept to clinic, of its two lead products.

NovaBiotics is a privately held company founded in 2004 by CEO Deborah O’Neil. The company is based in Aberdeen, UK and is led by a strong and experienced management team supported by first class key opinion leaders and scientific advisers.